

## The Need to Develop a Single Multi-OMICS Tool for IVF Embryo Selection

Faduola P\*

Senior Clinical Embryologist, Nordica Fertility Center, Lagos, Nigeria

\*Corresponding author: Paul Faduola, Senior Clinical Embryologist, Nordica Fertility Center, Lagos, Nigeria, Tel: +2347031932336; E-mail: sheyipaul06@yahoo.com


Rec date: Nov 06, 2015; Acc date: Nov 19, 2015; Pub date: Nov 22, 2015

Copyright: © 2015 Faduola P. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

### Introduction

In-vitro fertilization (IVF) patients are often made to rely on the judgement of embryologist to select embryo to be returned to the uterus in each treatment cycle. Most often, patients wish to know how the selected embryos are better off than the rest. This is especially true when they are displayed on the screen looking similar to each other. To an untrained eye, they may pass for the same quality but an embryologist use morphological criteria to distinguish the ones that have better quality. Some have argued that the experience of the embryologist is critical at this stage. But many have failed to understand why best of embryos transferred did not implant whereas poor quality embryos by these criteria have produced pregnancies [1,2]. The problem here is neither the skill of the embryologist nor the criteria for the selection but the complexity of the human embryo. The embryo is a very complex entity, with increasing complexity from fertilization to blastocyst [3]. Fertilization is usually evident by a two pronuclei which contain the whole genetic information of an embryo (genome). Soon after fertilization, a one-cell embryo is formed [4]. In order to cleave, it will require mRNAs (transcriptome) and proteins (proteome) from the maternal egg for initial development until the time when it own genome will be ready to carry on with this process [5]. An apparent feature here is the role of genome, proteome and transcriptome. It has been suggested that a healthy embryo will have less damage in it genome, proteome as well as the transcriptome. Because of the minimal damage, it is expected that less energy will be spent by the embryo to correct any defect so the metabolism (metabolome) in such an embryo would be quiescent rather than active [6]. It is therefore needful that the whole component that contributes to the complexity of the human embryo be holistically evaluated. The present morphological assessment criterion does not provide information to evaluate critical pathways of the embryonic genome, proteome, transcriptome and metabolome. These pathways have significant impact on viability of an embryo [7,8]. Recent efforts to address embryonic pathways had been component driven. This has greatly enriched our knowledge about the genetic sequence of an embryo and revealed the role of carrier molecules in altering embryonic genetic information [9-16]. Information about the protein an embryo secretes and metabolic profile of spent media has shown potentials in distinguishing between culture media from implanting and non-implanting embryo [17-21]. Also, embryos have been successfully interrogated to tell when and where gene expression is turned on or off as well as the number of RNAs involved to know how the gene is being expressed [22]. These are landmark achievements that have failed to improve on embryo selection significantly because they are component driven. Multi-OMICS is the greatest innovation the IVF world is anticipating. This is because it could allow information from the different pathways of genomics, proteomics, transcriptomics and metabolomics to be integrated simultaneously from a drop of spent media (Figure 1). The benefit of this approach is that human embryo can be evaluated holistically to allow a gene, protein or

metabolite that is poorly expressed in a single 'OMIC system due to low frequency to be captured by another 'OMIC system where it frequency is high. More so, single 'omic system only captures the activity that relates to it. For example, genomic sequencing only captures structural variations, but not RNA level. The RNA level is revealed when another 'OMIC technology such as RNA-seq is applied [23]. This may be one reason why researchers have failed to discover reproducible biomarkers that have the capability of predicting viability in embryo to approach 100% accuracy from a single 'OMIC technology till date.



**Figure 1:** A schematic outline of the steps to integrate multi-OMICS data for identification of any abnormality in an embryo.

Multi-OMIC system should be able to tell if an embryo has normal genes, proteins, ribonucleic acids and metabolic products. Any single embryo that is considered normal by this technology may be capable

of producing a clinical pregnancy. If a single technology is able to assess all these parameters, the possibilities of selecting a single embryo from a cohort that is viable may be increased. This may discourage multiple embryo transfer and reduce multiple births. A technology like this should be simple, rapid and affordable and should only be introduced after it has been properly validated.

One potential bottle neck to developing such a novel technology is proper homogenization of data in experiments and analytical protocols used in developing the individual OMIC biomarkers. This is necessary to avoid false interpretation due to false positive or negative data set as more potential biomarkers of embryo viability are discovered. Another potential bottle neck is developing a computational model that will allow unification of the different data set in a single platform. These bottle necks could be surmounted if skilled professionals in the different disciplines necessary for this discovery are involved early in the research. Only professionals that can apply best practices in sample collection, preparation and analysis should form part of the team. Translational Medicine tools and structures should be properly deployed for effective integration of these disciplines. Developing such a holistic system for selecting embryo will be ideal and better driven by a translational research team that will provide an interdisciplinary and multi-frontier approach.

## References

1. Bolton VN, Hawes SM, Taylor CT, Parsons JH (1989) Development of spare human pre-implantation embryos invitro: an analysis of the correlations among gross morphology, cleavage rates, and development to the blastocyst. *J In Vitro Fert Embryo Transf* 6: 30-35.
2. Gardner DK, Vella P, Lane M, Wagley L, Schlenker T, et al. (1998) Culture and transfer of human blastocysts increases implantation rates and reduces the need for multiple embryo transfers. *Fertil Steril* 69: 84-88.
3. George RP, Lee P (2009) Embryonic human persons. *Talking Point on morality and human embryo research*. *EMBO Rep* 10: 301-306.
4. Feenan K, Herbert M (2006) Can 'abnormally' fertilized zygotes give rise to viable embryos? *Hum Fertil (Camb)* 9: 157-169.
5. Bettegowda A, Lee KB, Smith GW (2008) Cytoplasmic and nuclear determinants of the maternal-to-embryonic transition. *Reprod Fertil Dev* 20: 45-53.
6. Leese HJ, Sturmey RG, Baumann CG, McEvoy TG (2007) Embryo viability and metabolism: obeying the quiet rules. *Hum Reprod* 22: 3047-3050.
7. Renard JP, Philippon A, Menezo Y (1980) In-vitro uptake of glucose by bovine blastocysts. *J Reprod Fertil* 58: 161-164.
8. Katz-Jaffe MG, McReynolds S, Gardner DK, Schoolcraft WB (2009) The role of proteomics in defining the human embryonic secretome. *Mol Hum Reprod* 15: 271-277.
9. Scott R, Tao X, Taylor D, Ferry KM, Treff NR (2010) A prospective randomized controlled trial demonstrating significantly increased clinical pregnancy rates following 24 chromosome aneuploidy screening: biopsy and analysis on day 5 with fresh transfer. *Fertil Steril* 94: S2.
10. Gutierrez-Mateo C, Colls P, Sanchez-Garcia J, Escudero T, Prates R, et al. (2011) Validation of microarray comparative genomic hybridization for comprehensive chromosome analysis of embryos. *Fertil Steril* 95: 953-958.
11. Fiorentino F, Spizzichino L, Bono S, Biricik A, Kokkali G, et al. (2011) PGD for reciprocal and Robertsonian translocations using array comparative genomic hybridization. *Hum Reprod* 26: 1925-1935.
12. Hodes-Wertz B, Grifo J, Ghadir S, Kaplan B, Laskin CA, et al. (2012) Idiopathic recurrent miscarriage is caused mostly by aneuploid embryos. *Fertil Steril* 98: 675-680.
13. Yang Z, Liu J, Collins G, Salem S, Liu X, et al. (2012) Selection of single blastocysts for fresh transfer via stand morphology assessment alone and with array CGH for good prognosis IVF patients: results from a randomized pilot study. *Mol Cytogenet* 5: 24.
14. Handyside AH (2011) PGD and aneuploidy screening for 24 chromosomes by genome-wide SNP analysis: seeing the wood and the trees. *Reprod Biomed Online* 23: 686-691.
15. Yang Z, Salem SA, Liu X, Kuang Y, Salem RD, et al. (2013) Selection of euploid blastocysts for cryopreservation with array comparative genomic hybridization (aCGH) results in increased implantation rates in subsequent frozen and thawed embryo transfer cycles. *Mol Cytogenet* 6: 32.
16. Treff NR, Scott RT Jr (2012) Methods for comprehensive chromosome screening of oocytes and embryos: capabilities, limitations, and evidence of validity. *J Assist Reprod Genet* 29: 381-390.
17. Dominguez F, Pellicer A, Simón C (2009) The human embryo proteome. *Reprod Sci* 16: 188-190.
18. Brison DR, Houghton FD, Falconer D, Roberts SA, Hawkhead J, et al. (2004) Identification of viable embryos in IVF by non-invasive measurement of amino acid turnover. *Hum Reprod* 19: 2319-2324.
19. Seli E, Botros L, Sakkas D, Burns DH (2008) Non-invasive metabolomics profiling of culture media using proton NMR correlates with reproductive potential of embryos in women undergoing in vitro fertilization. *Fertil Steril* 90: 2183-2189.
20. Gardner DK, Wale PL, Collins R, Lane M (2011) Glucose consumption of single post-compaction human embryos is predictive of embryo sex and live birth outcome. *Hum Reprod* 26: 1981-1986.
21. Pudakalakatti SM, Uppangala S, D'Souza F, Kalthur G, Kumar P, et al. (2013) NMR studies of preimplantation embryo metabolism in human assisted reproductive techniques: a new biomarker for assessment of embryo implantation potential. *NMR Biomed* 26: 20-27.
22. Brown TA (2002) *Genomes*. (2nd edn) Oxford: Wiley-Liss; Chapter 3, Transcriptomes and Proteomes.
23. Vucic EA, Thu KL, Robison K, Rybaczyk LA, Chari R, et al. (2012) Translating cancer 'omics' to improved outcomes. *Genome Res* 22: 188-195.